| 41.35 0.12 (0.29%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 51.84 |
1-year : | 55.22 |
| Resists | First : | 44.39 |
Second : | 47.27 |
| Pivot price | 42.84 |
|||
| Supports | First : | 39.72 | Second : | 33.04 |
| MAs | MA(5) : | 42.03 |
MA(20) : | 43.1 |
| MA(100) : | 37.95  |
MA(250) : | 27.81 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 23.1 |
D(3) : | 26 |
| RSI | RSI(14): 40.5 |
|||
| 52-week | High : | 50.81 | Low : | 15.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ URGN ] has closed above bottom band by 15.2%. Bollinger Bands are 45.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 41.88 - 42.15 | 42.15 - 42.41 |
| Low: | 39.96 - 40.32 | 40.32 - 40.64 |
| Close: | 40.8 - 41.36 | 41.36 - 41.86 |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Wed, 23 Sep 2026
UroGen Pharma Ltd. (URGN) stock price, news, quote and history - Yahoo Finance UK
Wed, 23 Sep 2026
UroGen Pharma Ltd. (URGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Thu, 10 Sep 2026
URGN: Zusduri's strong launch and next-gen pipeline position the company for growth and innovation - TradingView
Wed, 09 Sep 2026
UroGen Pharma (URGN) officer lines up 5,000-share sale from RSUs - stocktitan.net
Wed, 09 Sep 2026
Urogen Pharma: Upside After Bladder Cancer Launch (NASDAQ:URGN) - Seeking Alpha
Wed, 09 Sep 2026
UroGen Pharma (NASDAQ: URGN) officer plans 10,000-share sale after RSUs vest - stocktitan.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 3.4 (%) |
| Held by Institutions | 100.3 (%) |
| Shares Short | 5,120 (K) |
| Shares Short P.Month | 5,690 (K) |
| EPS | -1.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.72 |
| Profit Margin | -51.8 % |
| Operating Margin | 0.1 % |
| Return on Assets (ttm) | -18.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 199.1 % |
| Gross Profit (p.s.) | 3.5 |
| Sales Per Share | 3.86 |
| EBITDA (p.s.) | -1.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -159 (M) |
| Levered Free Cash Flow | -107 (M) |
| PE Ratio | -20.99 |
| PEG Ratio | 0 |
| Price to Book value | -15.26 |
| Price to Sales | 10.7 |
| Price to Cash Flow | -12.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|